CAR T-Cell Immunotherapy
The Leukemia & Lymphoma Society (LLS) announced the U.S. Food and Drug Administration (FDA) approval of a new, personalized cell therapy that supercharges the patient’s immune system to find and kill cancer cells. This therapy, known as CAR (chimeric antigen receptor) T-cell immunotherapy, is approved to treat adults with several types of relapsed and refractory non-Hodgkin lymphoma. Since 2015, LLS has supported the clinical trial leading to this approval through its Therapy Acceleration Program® (TAP). Through this innovative program, LLS partners directly with biotechnology companies, including Kite, a Gilead Company, the developer of this particular therapy, to help accelerate promising treatments. “Immunotherapy is dramatically changing the way we approach blood cancer treatment, and we are hopeful that this therapy will ultimately be applicable to patients with other types of cancers as well,” said Louis J. DeGennaro, Ph.D., LLS president and chief executive officer. “We identified Kite’s CAR T-cell therapy as having great potential for patients with lymphoma who have limited treatment options. This approval is a very significant advance for lymphoma patients and for the cancer community as a whole.” For the past two decades, LLS has invested more than $40 million in CAR T-cell immunotherapy research and development.
For more information visit www.lls.org